Elite Pharma reports positive bioequivalence study for generic anticonvulsant

Elite Pharmaceuticals, Inc. announced positive results from a pivotal bioequivalence study for an undisclosed generic anticonvulsant drug product. The study confirmed that the generic product is bioequivalent to its branded counterpart. The company is now preparing to file an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration. The market for this class of medications had sales of $840 million for the twelve months ending April 2026.